carsil kaetud tablett
sopharma ad - silümariin - kaetud tablett - 22,5mg 80tk
carsil kõvakapsel
sopharma ad - silümariin - kõvakapsel - 110mg 30tk
cardiopyrin gastroresistentne tablett
g.l. pharma gmbh - atsetüülsalitsüülhape - gastroresistentne tablett - 75mg 100tk; 75mg 30tk
aspirin cardio gastroresistentne tablett
bayer uab - atsetüülsalitsüülhape - gastroresistentne tablett - 100mg 98tk
nardil tablett
recipharm limited - fenelsiin - tablett - 15mg 100tk
cardiotop radiofarmatseutiline komplekt
rotop pharmaka ag - tehneetsium(99mtc)sestamibi - radiofarmatseutiline komplekt - 1mg 6tk
cardiodoron suukaudne lahus
weleda ag - homöopaatilised preparaadid - suukaudne lahus - 50ml 1tk
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - muud kardiaalsed preparaadid - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
segluromet
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - kõhu neoplasmid - antineoplastilised ained - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.